.avif)
Beckman Coulter Diagnostics Email Format
Medical Equipment Manufacturing
・
10,001-25,000 employees
・
Brea, CA, USA
Beckman Coulter Diagnostics is a global medical equipment company that develops advanced diagnostic solutions for hospitals, reference laboratories, and physician offices worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@beckmancoulter.com
Company Overview
Industry
Medical Equipment Manufacturing
Founded
1935
Headquarters
Brea, CA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Subsidiary
Website
Key Executives
Kevin O'Reilly (President), Tom Coffman (Senior Vice President and Chief Financial Officer), Terry Walsh (SVP Global Operations)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Beckman Coulter Diagnostics?
Beckman Coulter Diagnostics uses the first.last format on beckmancoulter.com, so Jane Smith would be jane.smith@beckmancoulter.com.
What diagnostic product lines does Beckman Coulter Diagnostics offer across its core testing disciplines?
Beckman Coulter Diagnostics offers instruments and assays across Chemistry, Immunoassay, Hematology, Urinalysis, Microbiology, Blood Banking, and Protein Chemistry, supporting routine and complex clinical testing in hospitals, reference laboratories, and physician office settings.
How many countries does Beckman Coulter Diagnostics operate in?
Beckman Coulter Diagnostics operates in more than 40 countries worldwide, with its headquarters in Brea, California and additional major locations in Miami, Florida, Chaska, Minnesota, and Munich, Germany.
Which parent company owns Beckman Coulter Diagnostics?
Beckman Coulter Diagnostics is an operating company of Danaher Corporation, a global life sciences and diagnostics company. Danaher acquired Beckman Coulter in 2011.
What is Beckman Coulter Diagnostics doing in the field of Alzheimer's disease testing?
Beckman Coulter Diagnostics received FDA Breakthrough Device Designation in January 2025 for a blood test designed to aid in identifying patients with amyloid pathology associated with Alzheimer's disease, developed on its DxI 9000 Access Immunoassay Analyzer platform.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating